Table 1.
Baseline characteristics of the acute stroke patients (acute ischemic stroke (AIS) and transient ischemic attack (TIA)).
Data are represented as mean ± standard deviation (SD). (NIHSS: National Institutes of Health stroke scale; TOAST: Trial of Org 10172 in Acute Stroke Treatment).
Fig 1.
Patients with acute or chronic cerebrovascular disease have lower ADAMTS13 levels and a higher VWF:ADAMTS13 ratio compared to healthy volunteers.
ADAMTS13 antigen levels from 104 patients with acute ischemic stroke, 112 patients with a chronic cerebrovascular disease (CCD) and 85 healthy volunteers, were measured. Levels of ADAMTS13 were plotted as a percentage of the level in a normal human plasma pool (NHP), consisting of pooled plasma from 20 healthy donors. VWF levels were measured previously and were used to calculate the VWF:ADAMTS13 ratios. Both ADAMTS13 levels [A] and VWF:ADAMTS13 ratios [B] are depicted in box-and-whisker plots indicating the first and third quartiles as well as the interquartile range (IQR, Tukey plot). Outliers outside the 1.5 IQR are visualized by single dots. ADAMTS13 levels and the VWF:ADAMTS13 ratios showed significant differences over the three groups. Data were analyzed using a Kruskal-Wallis test with a Dunn's multiple comparison test. *: p < 0.05; ****: p < 0.0001.
Table 2.
Univariate analysis of ADAMTS13 levels and the VWF:ADAMTS13 ratio with demographic and clinical parameters.
Data are represented as mean ± standard deviation (SD). Data were analyzed by an independent samples Mann-Whitney U test or Kruskal-Wallis test, where applicable. (AIS: acute ischemic stroke; TIA: transient ischemic attack; NIHSS: National Institutes of Health stroke scale).
Table 3.
Multivariate analysis of ADAMTS13 levels and the VWF:ADAMTS13 ratios with demographic and clinical parameters.